Previous studies show that the RelB-silencing suppresses migration and invasion abilities of DU145 prostatic cancer cells and SPC-A1 lung cancer cells by decreasing the expression of Integrin β1 [22, 25]. Here, RELB is linked to prostate carcinoma.